

Persetujuan Pelaksanaan Uji Klinik (PPUK) Tahun 2020

NO	Judul Protokol Uji Klinik	Sponsor /CRO	CENTER	PENELITI	No. PPUK	Tanggal PPUK
1	<i>A Prospective , Randomized, Active Treatment - controlled, evaluator blinded (radiologist reviewer and physician evaluator) multicenter study to establish the superiority of a hyaluronan - based scaffold (Hyalofast) with Autologous bone marrow aspirate concentrate (BMAC) in the treatment of articular knee cartilage defect lesions in comparison to control (microfracture treatment)</i>	Ani Therapeutics US America / PT. Pharma Metrics	1. RS Medistra 2.RS Royal Progress	1. Dr.dr. Andri Maruli TuaLubis., SpOT(K) 2. dr. Bobby N.Nelwan, SpOT	RG.01.06.321.01.20.0045	06-Jan-20
2	<i>Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Noninferiority to PQed TCV and TyphoidVi Polysaccharide Vaccine (Phase III)</i>	PT Biofarma, Bandung	Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran Universitas Indonesia	dr. Bernie Endyarnie Medise, Sp A(K), MPH	RG.01.06.321.01.20.0161-0163	20-Jan-20
3	<i>A Randomized Double Blind Controlled Clinical Study to Evaluate Efficacy and Safety of Diclofenac with Heparin (Diclofenac Sodium 1 % and Heparin 200 IU w/w) Gel Compared to Gel Contained Diclofenac Sodium 1% Only and Heparin 200 IU w/w Only in Subjects with Acute Blunt Soft Tissue Injuries</i>	PT. Tunggal Idaman Abdi / PT. Equilab	Klinik Pusat Pelatihan Olahraga Pelajar (PPOP) Indonesia Sports Medicine Centre (ISMC) RS Jakarta	dr. Zeth Boroh, Sp.KO	RG.01.06.32.321.03.20.0332	09-Mar-20
4	<i>"A Dose Escalation Evaluation of Safety and Tolerability and Pharmacokinetics of Adrecizumab – a Humanized Monoclonal Antibody Against Adrenomedullin (ADM) in Patients with Acute Heart Failure Requiring Hospitalization" Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)</i>	Great Network Italy/PT. Prodia Diacro Laboratories	RSUP Dr. Sardjito Yogyakarta	dr. Anggoro Budi Hartono , M.Sc., Ph,D, Sp.PD., Sp.JP	RG.01.06.321.03.20.0330	09-Mar-20
5	Dosis Tinggi Rifampisin 2 bulan versus dosis standar rifampisin 4 bulan untuk pengobatan infeksi laten TB (iltb) : sebuah uji klinik (2R2)	McGill International TB Centre, Canada	Fakultas Kedokteran Universitas Padjajaran Bandung	Prof. Rovina Ruslami., dr., SpPD, PhD	RG.01.06.321.03.20.0346	16-Mar-20
6	<i>Open Label Randomised Controlled Trial of Efepoetin Alfa For Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not On Dialysis (ND-CKD). A Non Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)</i>	PT. Kalbe Genexine Biologics	1. RS PGI Cikini 2. RS Islam Jakarta, Cempaka Putih 3. RS Islam Jakarta Pondok Kopi 4. RSUP Fatmawati 5. RSUPN Cipto Mangunkusumo	1.Dr. Tunggal D. Situmorang, SpPD-KGH 2. Dr. Kuspudji Dwitanto R, SpPD-KGH 3. Dr. Kuspudji Dwitanto R, SpPD-KGH 4. Dr. J Sarwono, SpPD-KGH 5. Dr. Pringgodigdo Nugroho, SpPD-KGH	R-RG.01.06.32.321.03.20.034	16-Mar-20

7	<p><i>An International Randomise Trial of Additional Treatments For COVID 19 In Hospital Patients Who Are All Receiving the Local Standard of Care (Solidarity Trial)</i></p>	<p>WHO / Badan Penelitian dan Pengembangan Kesehatan, Kemenkes RI</p>	<p>1. RS Kandou Manado 2. RS Udayana 3. RS Wahidin Suroso 4. RSUD Ambarawa 5. RS Dr. M. Djamil 6. RSPI Sulianti Suroso 7. RSUD Kariadi Semarang 8. RSUD Soetomo 9. RSUD Dr. Hasan Sadikin 10. RSJ Prof Dr. Soerojo 11. RSCM 12. RS H. Adam Malik 13. RSUD Dr. Moewardi, Solo 14. RSUP Dr. Sardjito, Yogyakarta 15. RSUD Dr. Achmad Mochtar, Bukit Tinggi</p> <p>16. RSUD Saiful Anwar 17. RS Universitas Airlangga 18. RSUD Dr. Arifin Achmad 19. RSUP Persahabatan 20. RS Yarsi 21. RS Esnawan Antarksa 22. RS Wisma Atlet 23. RS Fatmawati 24. RS Sanglah</p>	<p>Peneliti Utama : Dr.dr.Irmansyah, Sp.KJ(K) dan Prof.dr. Menaldi Rasmin, Sp.P(K) Peneliti Center :</p> <p>1. dr. Agung Nugroho, SpPD-KPTI 2. Dr. dr. Agus Somnia, SpPD-KPTI 3. Dr.dr Irawaty Djaharuddin, Sp.P(K) 4. dr. Hayu Arya Ratna Taufiqi, SpP 5. dr. Irvan Medison, SpP 6. dr. Pompimi Agustina Sitompul, SpP(K) 7. dr. Sofyan Budi Rahardjo, Sp.P(K) 8. Dr.dr. Soedarsomo, SpPK(K) 9. dr. Yovita Hartantri, SpPD-KPTI(K) 10. dr. Harli Amir Mahmudi, SpPD 11. Dr. Ceva Wicaksono Pitoyo, SpPD-KP, KIC, FINASIM 12. Dr. Ade Rahmarini, Sp.P(K) 13. Dr.dr. Harsini, SpP(K) 14. Dr. Bambang Sigit Riyanto, SpPD-KP, FINASIM 15. Dr. Deddy Herman, Sp.P</p> <p>16. Dr. Yani Jane Sugiri, Sp.P(K) 17. Prof. Dr.dr. Muhammad Amin, Sp.P(K) 18. Dr.Indr Yovi, Sp.P(K) 19. dr. Fathiyah Isbariah, Sp.P(K) 20.Dr.dr.Indra Kusuma, M.Biomed 21.Dr. Flora Eka Sari, Sp.P 22.Mayjen TNI Bambang Swi HS, Sp.B. FinaCS., M.Si 23.Dr. Aryan Yohanes, SpPD 24.dr. I. Gede Sajnadiyaram, SpPD-KP, FINASIM</p>	<p>PP. 01.01.1.3.04.20.49</p>	<p>05-Apr-20</p>
8	<p>Uji Klinik Favipiravir (AVIGAN) untuk pengobatan pada pasien Covid 19 di beberapa Rumah Sakit Rujukan Covid 19 di Jakarta</p>	<p>PT. Pertamina Bina Medika IHC</p>	<p>1. RSCM 2. RS Persahabatan 3. RS Pertamina Jaya 4. RS Pusat Pertamina 5. RS PELNI 6. RSPI Sulianti Suroso 7. RSPAD Gatot Subroto</p>	<p>Study Coordinator : Dr.Dante Saksono Harbuwono, SpPD-KMED,PhD 1. Dr. Martin Rumende , Sp.PD, KP, FINASIM, FCCP ; Dr. Adityo Susilo, Sp.PD, KPTi 2. DR. dr. Erlina Burhan, MSc, Sp.P (K) 3. Dr. Nyoman Sp.P 4. Dr. Wayu, Sp.P 5. Dr Robert Sinto, Sp.PD ; Dr. Erlang Samoedra, SpPD; Dr. Prasenhadi, Sp. P-KIC, PhD 6. Dr. Pompini, SpP 7. Dr. Retno Wihastuti, SpP</p>	<p>PP. 01.01.1..3.04.20.51</p>	<p>10-Apr-20</p>
9	<p><i>Comparison of Immunogenicity and Safety of DTP HB Hib (Biofarma) with Pentabio vaccine Primed with Recombinant Hepatitis B at Birth dose(using different source of Hepatitis B) in Indonesian Infants</i></p>	<p>PT. Bio Farma (Persero), Bandung</p>	<p>RS Hasan Sadikin / Fakultas Kedokteran Universitas Padjajaran Bandung</p>	<p>Dr. Eddy Fadlyana, dr., Sp.A(K)., M.Kes</p>	<p>R- RG.01.06.32.321.04.20.313</p>	<p>13-Apr-20</p>

10	<i>Efficacy and safety of convalescent plasma transfusion administered as adjunctive treatment to standard treatment in moderate, severe, and/or critically ill patients with COVID19</i>	Kementerian Riset dan Teknologi/ Badan Riset dan Inovasi Nasional (Kemenristek BRIN)	<ol style="list-style-type: none"> 1. RSUP Dr. Syaiful Anwar Malang 2. RSUP Dr. Sardjito 3. RSUD Dr. Soetomo 4. RS UNAIR 5. RSUP Dr. Soeradji Tirtonegoro 6. RSPI Sulianti Saroso 7. RSUD Dr. moewardi Solo 8. RSUP Dr. Kariadi Semarang 9. RSUP Dr. M.Djamil Padang 10. RSUP Dr. Wahidin Sudirohusodo, Makassar 	Koor Peneliti: Dr. Jarir At Thobari, PhD <ol style="list-style-type: none"> 1. Dr. Putu Moda A, SpPD, K-Med 2. Dr. Johan Kurnianda, SpD-KHOM 3. Dr. Bambang Pujo Semedi, SpAN.KIC 4. Dr. Hamzah, SpAn, KNA 5. Dr. Achmad Thabrani, Sp.PD 6. Dr. Adiatmo Pratomo, SpPD 7. Dr. Jatu Aphridasari, Sp.P(K) 8. DR. dr. Santosa, SpD-KHOM 9. Dr.dr.Iza Wahid, SpPD-KHOM 10. Dr. Faisal Muchtar, SpAn. KIC 	R-RG.01.06.3.05.20.156	11-Mei-20
11	Penilaian Efikasi dan Keamanan Injeksi BDB-001 untuk pengobatan covid 19 dengan Pneumonia Berat dan Progresif , Suatu Uji Klinik Fase II <i>add-on</i> pada terapi konvensional , paralel, acak dan terbuka	Staidson (Beijing) Biopharmaceutical Co., Ltd China dan PT. Etana / CRSU	<ol style="list-style-type: none"> 1. RSUP Persahabatan 2. RS Pasar Minggu 3. RS Cengkareng 	<ol style="list-style-type: none"> 1.DR. dr. Erlina Burhan, MSc, Sp.P (K) 2.dr. Sri Dhuny Atas Asri, Sp.P, FISR 3.dr. Puji Astuti, SpP 	RG.01.06.1.30.06.20.36	15-Jun-20
12	Uji klinik fase III, multisenter, acak terkontrol, membandingkan efikasi dan keamanan kombinasi Lopinavir/Ritonavir-Azythromycin, Lopinavir/Ritonavir-Doxycycline dan Hydroxychloroquin–Azythromycin dengan terapi standar pada pasien COVID-19 yang dirawat di rumah sakit dengan derajat ringan, sedang, dan berat yang tidak menggunakan ventilator	Badan Intelijen Negara (BIN)	<ol style="list-style-type: none"> 1.RSU Universitas Airlangga 2.RSUD Bhakti Dharma Husada, Surabaya 3.RS Soewandi 4.RSUD Lamongan 5.RSUD Kediri 6.RSPAD Gatot Subroto 	Dr. Purwati, dr., Sp.PD., FINASIM.	PP.01.01.1.3.07.20.06	03-Jul-20
13	<i>Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)</i>	University of Oxford / EOCRU (EIJKMAN-Oxford Clinical Research Unit)	<ol style="list-style-type: none"> 1.RSUPN Cipto Mangunkusumo, Jakarta 2.RSUP Persahabatan, Jakarta 	Peneliti Utama: dr. Erni Juwita Nelwan, SpPD,K-PTI,FACP-FINASIM, PhD Peneliti Pendamping : <ol style="list-style-type: none"> 1. Dr. dr. C. Martin Rumende, Sp.PD-KP 2. DR. dr. Erlina Burhan, MSc, Sp.P (K) 	RG.01.06.1.3.07.20.08	15-Jul-20

14	Uji klinik pemberian plasma konvalesen sebagai terapi tambahan Covid 19	Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI	<ol style="list-style-type: none"> 1. RSUP Dr. Syaiful Anwar, Malang ; 2. RSUP H. Adam Malik, Medan ; 3. RSUP Dr. M. Hoesin, Palembang; 4. RSUP Dr. Sardjito, Yogyakarta; 5. RSUD Dr. Soetomo, Surabaya; 6. RS Universitas Airlangga, Surabaya; 7. RS Dr. Soeradji Tirtonegoro, Klaten; 8. RS Sulianti Saroso, Jakarta; 9. RSUP Persahabatan, Jakarta; 10. RSPAD Gatot Subroto, Jakarta; 11. RSUPN Dr. Cipto Mangunkusumo, Jakarta; 12. RSUP Fatmawati, Jakarta; 13. RSAL Dr. Ramelan Surabaya; 14. RS Dr. Moewardi, Solo; 15. RS Dr. Kariadi, Semarang; 16. RS Dr. M Djamil, Padang; 17. RSUP Sanglah, Denpasar; 18. RS Univ. Udayana, Bali; 19. RS Dr. Wahidin Sudirohusodo, Makassar; 20. RS Dr. Tadjuddin Chalid, Makassar; 21. RSUP Prof. Dr. R.D. Kandou, Manado; 22. RS Universitas Indonesia, Jakarta; 23. RSUD Sidoardjo, Sidoardjo; 24. RSUP Dr. Hasan Sadikin, Bandung; 25. RS YARSI, Jakarta; 26. RSUD Dr. Haryoto, Lumajang; 27. RSKD Dadi, Makassar; 28. RS Universitas Hasanuddin, Makassar; 29. RS Dr. Suyoto, Jakarta; 30. RSUD Pasar Minggu, Jakarta 	Peneliti Utama : <ol style="list-style-type: none"> 1. Prof. David Hanjono Muljono, SpPD, PhD 2. Dr.dr. Irmansyah, Sp.KJ(K) 	RG.01.06.1.3.07.20.10	20-Jul-20
15	Studi Terapeutik Evaluasi Efikasi dan Keamanan DW-MSD pada Pasien COVID-19: Studi Acak, Tersamar Ganda, dan Terkontrol Plasebo	PT. Daewoong Infion	RSUP Dr. Wahidin Sudirohusodo, Makassar	dr. Irawaty Djaharuddin, Sp.P(K)	RG.01.06.1.3.07.20.11	24-Jul-20
16	<i>A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Immunogenicity, Safety and Efficacy of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18 Years and above in Indonesia</i>	PT. Biofarma, Bandung	RS Hasan Sadikin Bandung	Prof. Dr. Kusnandi Rusmil, dr., Sp.A(K), MM	RG.01.06.1.3.07.20.09	27-Jul-20
17	<i>High dose oral rifampicin to improve from adult tuberculosis meningitis (HARVEST)</i>	<i>Infectious Disease Institute Limited, Uganda dan Universitas Padjajaran</i>	<ol style="list-style-type: none"> 1. RSUP Hasan Sadikin 2. RSUP Cipto Mangunkusumo 	<ol style="list-style-type: none"> 1. dr. Ahmad Rizal Ganiem, Sp.S(K), PhD 2. dr. Darma Imran, SpS(K) 	B- RG.01.06.32.321.08.20.513 dan 514	03-Agu-20

18	Aplikasi Sel Punca Mesenkimal Asal Tali Pusat Sebagai Terapi Adjuvan pada Pasien Pneumonia COVID-19 Kritis	PT. Kimia Farma	1. RSPI Sulianti Saroso, Jakarta 2. RSUPN Cipto Mangunkusumo, Jakarta 3. RS Persahabatan, Jakarta 4. RS Universitas Indonesia, Jakarta	1. Dr. Pompini Agustina S, Sp.P(K) 2. Dr. dr. Dita Aditiansih, Sp-An-KIC 3. DR. dr. Erlina Burhan, MSc, Sp.P (K) 4. Dr. dr. Dita Aditiansih, Sp-An-KIC	RG.01.06.1.3.08.20.14	13-Agu-20
19	<i>Efficacy, Safety dan Immunogenicity of Rotavirus RV3 Vaccine (BioFarma) in Neonates, Lot to Lot Consistency and Antigen Interference with Co-Administered EPI Vaccines</i>	PT Biofarma, Bandung / IQVIA Indonesia	<i>Pediatric Research Center, Universitas Sebelas Maret</i>	Koordinator Studi Dr. Jarir At Thobari, PhD Peneliti Center : dr. Hary Wahyu N, M.Kes., Sp.A(K)	B-RG.01.06.3.32.09.20.795	18-Sep-20
			<i>Center for Child Health Pediatric Research Office Universitas Gadjah Mada (CCH-PRO UGM)</i>	Dr.dr. Titis Widowati, Sp.A(K)	R-RG.01.06.3.32.10.20.862	07-Okt-20
20	<i>Reducing the risk of Plasmodium vivax relapse after acute Plasmodium falciparum malaria in co-endemic areas - a randomized controlled trial (PRIMA)</i>	<i>Menzies School of Health Research, Australia / Eijkman-Oxford Clinical Research Unit</i>	Fakultas Kedokteran Universitas Indonesia, Lembaga Eijkman dan Eijkman-Oxford Clinical Research Unit.	Prof. dr. Inge Sutanto, MPhil, SpParK	R-RG.01.06.32.321.09.20.630	28-Sep-20
21	Fase III, Acak – Terbuka, Uji Klinis Efikasi dan Keamanan Favipiravir Pada Pasien Covid-19 di Indonesia	Pusat Penelitian dan Pengembangan Sumber Daya dan Pelayanan Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan	1.RSPI Sulianti Saroso, Jakarta 2.RSJ Soerojo, Magelang 3.RSUP Dr Karyadi, Semarang 4. RST Soedjono, Magelang 5. RS Merah Putih, Magelang	Peneliti Utama : Dr. dr. Armedy Ronny Hasugian, M.Biomed Peneliti Center : 1. dr.Adria Rusli, SpP(K) 2.dr. Harli Amir Mahmudji, SpPD, KEMD 3.dr. Sofyan, SpP(K) 4.dr. Dwi Hartanto, Sp.P., FIRS 5. dr.Raha Sulistyani, SpPD	RG.01.06.1.3.10.20.30	07-Okt-20
22	<i>Efficacy , Safety, and Immunogenicity of Rotavirus RV 3 Vaccine (BioFarma) in Neonates, Lot to Lot Consistency and Antigen Interference with Co-Administered EPI Vaccines (Phase III)</i>	PT. Biofarma, Bandung / IQVIA Indonesia	<i>Center for Child Health Pediatric Research Office Universitas Gadjah Mada (CCH-PRO UGM)</i>	Dr. Jarir At Thobari, PhD	R-RG.01.06.3.32.10.20.862	07-Okt-20
23	<i>Persistence and Long Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Adults, Adolescents, Children and Infants</i>	PT. Bio Farma (Persero), Bandung	Departemen Anak, FK Universitas Indonesia.	Bernie Enyarnie, dr, SpA(K), MPH	RG.01.06.1.3.11.20.33	10-Nov-20

24	<i>A Multi center, Randomized, Double-blind, Parallel design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSF-v13 Compared to Standard of care after intravenous (IV) administration with Add-on Standard of care in COVID-19 Moderate to Severe Patients</i>	ImmuneMed Inc, Korea Selatan / PT. Prodia Diacro Laboratories	1.RSUP Persahabatan, Jakarta 2.RSUD Pasar Minggu, Jakarta 3. RS Pertamina Pusat	1. DR. dr. Erlina Burhan, MSc, Sp.P (K) 2. dr. Sri Dhuny Atas Asri, Sp.P 3. dr. Wahyuningsih Suharno, Sp.P	RG.01.06.1.3.07.20.25	01-Des-20
25	<i>A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin Nanoparticle Albumin Bound (nab)-Paclitaxel) vs Chemotherapy (Carboplatin nab-Paclitaxel) as First-Line Therapy for Locally Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)</i>	Shanghai Henlius Biotech / PT. Prodia Diacro Laboratories	1.RS Saiful Anwar 2.RS Kanker Dharmais 3. RSUP Sardjito, Yogyakarta 4. RS Kariadi Semarang	1. Dr. Arif Riswahyudi Hanafi, SpP(K) 2. Dr. Suryanti Dwi Pratiwi, SpP(K), FISR, FAPSR 3.dr. Johan K, SpPD-khom, FINASIM 4. dr. Eko Adhi Pangarsa, SpPD-KHOM	RG.01.06.1.3.07.20.25	01-Des-20
26	Evaluasi Pemberian Remdesivir pada Pasien COVID-19 di RSUP Persahabatan Jakarta	PT. AmaroX Pharma Global	RSUP Persahabatan	DR. dr. Erlina Burhan, MSc, Sp.P (K)	RG.01.06.1.3.12.20.2	01-Des-20
27	Uji Klinik Adaptif Fase I Vaksin yang berasal dari Sel Dendritik Autolog yang Sebelumnya Diinkubasi dengan <i>Spike Protein Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2)</i> pada Subjek yang Tidak Terinfeksi COVID-19 dan Tidak Terdapat Antibodi Anti SARS-CoV-2	Badan Penelitian dan Pengembangan Kesehatan / PT. AIVITA Biomedika Indonesia	RSUP Dr. Kariadi, Semarang	Peneliti Utama : 1. Dr Djoko Wibisono, SpPD, KGH, FINASIM 2. dr. Muhammad Karya, M.Kes Peneliti Center : Dr.dr. Muchlis Achsan Udji, SpPD-KPTI, FINASIM	RG.01.06.1.3.12.20.27	02-Des-20
28	<i>An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19* Short title: Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) - Protocol No: INSIGHT 013</i>	1.Institute of Allergy and Infectious Disease (NIAID), National Institute of Health (NIH), Amerika / The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) 2. Puslitbang Sumber Daya dan Pelayanan Kesehatan, Balitbang Kesehatan, Kemenkes RI	1.RSUPN dr Cipto Mangunkusumo Jakarta 2. RSUD Dr Soetomo, Surabaya 3.RSU Kab Tangerang, Banten	1.dr. Adityo SpPD, K-PTI 2.Prof. dr. Usman Hadi, Ph.D, SpPD, K-PTI 3.dr. Prasetyo Hariadi, SpP .	RG.01.06.1.3.12.20.41	08-Des-20

29	Studi Efektivitas dan keamanan kuinin sulfat pada subjek dewasa penderita COVID-19 yang dirawat di rumah sakit : sebuah studi adaptif, multicenter, acak, tersamar ganda, terkontrol	Kementerian Riset dan Teknologi/ Badan Riset dan Inovasi Nasional (Kemenristek BRIN) / PT. Prodia DiaCRO Laboratories	1. RS Universitas Indonesia 2.RSPAD Gatot Soebroto 3.RSUP Dr. Hasan Sadikin	Koordinator Nasional : 1. Prof. DR. Apt. Keri Lestari, S.Si, M.Si 2. Dr.Ir.Irmansyah, Sp.KJ(K) 3. Prof. Dr.dr. Cissy RachianaSudjana Prawira, SpA(K), M.Sc Peneliti Center : 1. dr. Raden Rara Diah Handayani, Sp.P(K). 2. dr. Dewiyana Andari Kusmana, Sp.P 3. dr. Iceu Dimas Kulsum, Sp.PD, Sp.P	RG.01.06.1.3.12.20.44	10-Des-20
30	<i>A Phase 2, randomized, double-blind, placebo-controlled, parallel group, single administration study to evaluate the safety and efficacy of GX-17 in elderly patient with asymptomatic or mild symptoms of severe acute respiratory syndorome coronavirus (SARS-CoV-2) infection</i>	PT Kalbe Genexine Biologics	1.RS Persahabatan 2.RS Mitra Keluarga Kelapa Gading 3.RSDC Wisma Atlet 4.RS Mitra Keluarga Kemayoran	1.DR. dr. Erlina Burhan, MSc, Sp.P (K) 2.Dr. Frans Liwang, Sp.PD 3.dr. Andika Chandra P PhD, Sp.P(K), FAPSR 4.Dr. Chanda Wibowo, SpPD-KGH, FINASIM	RG.01.06.1.3.07.20.349	29-Des-20
31	<i>Efficacy and safety of normoxic allogenic umbilical cord mesenchymal stem cells administered as adjunctive treatment to standard treatment in severe patients with COVID-19</i>	Kementerian Riset dan Teknologi/ Badan Riset dan Inovasi Nasional (Kemenristek BRIN) / PT. Bifarma Adiluhung	1. RSUD Dr. Moewardi, Surakarta 2. RSUP Dr. Sardjito, Yogyakarta 3. RSUP Dr. Hasan Sadikin Bandung	Koordinator Peneliti : DR. Dr. Bintang Soetjahjo, SpOT(K) 1. Dr.dr. Arief Nurudhin, SpPD, KR, FINASIM 2. Prof. DR. Dr. Samekto Wibowo, P.Far, K, Sp.FK(K), SpS(K) 3. Dr. Ahmad Faried, SP.BS(K), Ph.D	RG.01.06.1.3.12.20.01	30-Des-20